Dalfampridine in multiple sclerosis: From symptomatic treatment to immunomodulation

Carmen Espejo, Xavier Montalban

Research output: Contribution to journalReview articleResearchpeer-review

25 Citations (Scopus)


Multiple sclerosis (MS) is a neurodegenerative disease that is deemed to affect more than 2.1 million people worldwide, and for which there is no cure. Early symptoms of MS are believed to result from axonal demyelination leading to slowing or blockade of impulse conduction. The blockade of K+ channels has been proven to improve conduction deficiencies secondary to demyelination in patients with MS. Dalfampridine is a K+ channel blocker that was recently approved by FDA for the symptomatic treatment of ambulation hardship in MS. Understanding the mechanisms by which Dalfampridine exerts its therapeutic effects is a complex issue as it blocks a wide variety of K+ channels that are distributed across multiple cell types in the nervous system but also in the immune system, and because of their molecular identities remaining unknown. This review describes Dalfampridine potential roles at the cellular and molecular levels in MS pathogenesis. (C) 2011 Elsevier Inc. All rights reserved.
Original languageEnglish
Pages (from-to)84-92
Number of pages9
JournalClinical Immunology
Issue number1
Publication statusPublished - Jan 2012


  • 4-aminopyridine
  • Dalfampridine
  • Fampridine-SR
  • Multiple sclerosis
  • Potassium channel blocker
  • Symptomatic treatment


Dive into the research topics of 'Dalfampridine in multiple sclerosis: From symptomatic treatment to immunomodulation'. Together they form a unique fingerprint.

Cite this